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Dear Editor,
I read with great interest the study by Suzuki et al. [1], in
which the authors conclude that fluctuations in C3 levels
may be monitored to estimate disease activity along with
hematuria, proteinuria and renal function in immunoglob-
ulin (Ig)A nephropathy. However, some equivocal results
lead us to discuss the conclusions of the study.
Firstly, the fluctuated mean ± SD values in the group
with the deterioration are so similar to the groups with
amelioration that we consider the difference was to a large
extent owing to the number of patients in the groups. In
fact, the authors suggested such a possibility in the dis-
cussion section regarding the corticosteroid-administered
group. Additionally, the suspicious results in Group II and
Group III are contrary to the main theme of the study.
Instead of basing their explanation of Group III on a pre-
vious report about obesity and age, I suggest to compare
fluctuations of C3 in their older IgA nephropathy patients
with obesity. As a matter of fact, body weight and body
mass index are not significantly different from other groups
in Group III at Table II. Triglyceride and total cholesterol
levels need to be confirmed for groups II–III and fasting
plasma glucose for groups I–III. So, it is difficult to
consider a reliable link between C3 levels and disease
activity or metabolic background.
Secondly, the authors say that C3 is consumed in IgA
nephropathy despite being in the cutoff range. I wonder
about the explanation of C4 and CH50 decrement, despite
their being in the cutoff range in the study.
Thirdly, there are some technical problems related to
standardization of the quantification of complement levels.
The standardization and the quality control of the assay is
to a large extent missing [2]. I suggest confirming the
results of the study either with different measurement
methods or commercial kits.
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